The Southeastern region of the U.S. is an exciting area where biotechnology has been growing over the past few decades. With respect to the exciting and cutting-edge biotherapeutics area of cell therapy, we find 22 cell therapy companies headquartered in the Southeast region that have at least 1 cell biology program in our BiopharmIQ company database. Twelve of these companies are public companies (FIG. 1 📷). In this region, Florida, Maryland, and North Carolina have the largest number of cell therapy company headquarters (FIG. 1 📷).
One of the larger companies headquartered in the Southeast that sponsors at least 1 cell therapy program is United Therapeutics. Precigen is another public company headquartered in the Southeast that has a significant technical focus related to cell biology. Furthermore, private companies like Longeveron focus their R&D and product development efforts on cell therapies. See below for more info on these biopharma companies with headquarters in the Southeast U.S.
Representative Company Snapshots
Southeast U.S. headquartered cell therapy companies
Longeveron with headquarters in Miami, FL, is a private, clinical-stage biotechnology company, that develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from the bone marrow of young healthy adult donors.
United Therapeutics (Nasdaq: UTHR) with co-headquarters in Silver Spring, MD, and Research Triangle Park, NC, has commercial and investigational programs with diverse platforms that span small molecules, antibodies, organ therapies, and cell therapies, for example. It is funding a cell therapy research program being conducted by Northern Therapeutics, Inc., to which United Therapeutics has exclusive U.S. rights. This program, called GEM, is a cell-based gene therapy program focused on developing effective, transiently transfected, off-the-shelf therapeutics for pulmonary diseases or acute inflammatory diseases.
Precigen (Nasdaq: PGEN) with headquarters in Germantown, MD, is a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Its technologies include UltraCAR-T, a multigenic autologous CAR-T platform that utilizes Precigen's advanced non-viral Sleeping Beauty system to simultaneously express an antigen-specific CAR to specifically target tumor cells, mbIL15 for enhanced in vivo expansion and persistence, and a kill switch to conditionally eliminate CAR-T cells for a potentially improved safety profile.
Are you a CRO, CMO, or Biopharma vendor? Get a list of 100's of biopharma companies with cell therapy products. Perfect for sales and business development activities. Access our free report here: https://www.biopharmiq.com/cell-therapy-companies-report
Original published: 01/17/24 RF
This article is not investment or legal advice.